Business
Oculis to Host In-Person and Virtual R&D Day on Key Business Updates and the Development Plans for Privosegtor (OCS-05) in Acute Optic Neuritis and Beyond
ZUG, Switzerland, April 01, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (“Oculis” or the “Company"), a global biopharmaceutical
About this update from Oculis Holding Ag
[{"type":"text","content":"ZUG, Switzerland, April 01, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (“Oculis” or the “Company\"), a global biopharmaceutical company focused on innovations addressing ophthalmic and neuro-ophthalmic diseases with significant unmet medical needs, today announced that it will host an in-person and virtual R&D Day on Tuesday, April 15, 2025 from 10:00 AM to 12:00PM ET at the Intercontinental New York Barclay hotel. To register for the event, click here. The event will provide an update on Oculis’ portfolio of innovative late-stage clinical candidates, highlight recent clinical data and next steps, as well as discuss future development programs and business strategy. It will feature world-renowned key opinion leaders (KOLs): Retina: David Boyer, MD (Keck School of Medicine, University of Southern California, and Retina Vitreous Associates Medical Group) Arshad Khanani, MD, MA, FASRS (Reno School of Medicine, University of Nevada, and Sierra Eye Associates);Baruch D. Kuppermann, MD, PhD (Department of Ophthalmology, University of California, Irvine and Gavin Herbert Eye Institute)Sebastian Wolf, MD, PhD (Department of Ophthalmology, University of Bern); Inflammation and precision medicine: Anat Galor, MD, MSPH (Bascom Palmer Eye Institute, Miller School of Medicine, University of Miami); Neuro-ophthalmology: Mark Kupersmith, MD (Departments of Ophthalmology and Neuroscience, Mount Sinai);Leonard Levin, MD, PhD (Departments of Ophthalmology & Visual Sciences and Neurology & Neurosurgery, McGill University);Pablo Villoslada, MD, PhD (Department of Neurology, Hospital del Mar, Pompeu Fabra University and Department of Neuroscience, Stanford University); The presentations will include an update on progress with both Phase 3 DIAMOND trials of OCS-01 eye drops in diabetic macular edema (DME), Licaminlimab (OCS-02)’s development plan with precision medicine in dry eye disease (DED) and an expanded data analysis from the ACUITY Phase 2 trial as well as the development plans for Privosegtor (OCS-05) in acute optic neuritis and beyond. The event will also outline Oculis’ portfolio strategy to drive pipeline value and maximize resource deployment. A live question and answer session will follow the formal presentations. - END - About OCS-01 eye drops and the OPTIREACH® technologyLeveraging Oculis’ proprietary technol...